INDIAGLYCONSEQ2FY2618 November 2025

India Glycols Limited

5,335words
4turns
0analyst exchanges
0executives
Key numbers — 40 extracted
rs,
2025 The Manager (Listing) BSE Limited 1st Floor, New Trading Ring, Rotunda Building, P.J. Towers, Dalal Street, Bandra (East), Mumbai – 400 001 The Manager (Listing) National Stock Exchange of I
13%
Overview Figures in ₹ Cr. Gross Revenue Net Revenue EBITDA & EBITDA Margin PAT & PAT Margin +13% 2,144 2,412 +14% 961 1,092 12.4% 14.6% 5.1% 5.9% +33% 160 120 +31% 50 65 Q2
14%
₹ Cr. Gross Revenue Net Revenue EBITDA & EBITDA Margin PAT & PAT Margin +13% 2,144 2,412 +14% 961 1,092 12.4% 14.6% 5.1% 5.9% +33% 160 120 +31% 50 65 Q2FY25 Q2FY26 Q2FY25
12.4%
e Net Revenue EBITDA & EBITDA Margin PAT & PAT Margin +13% 2,144 2,412 +14% 961 1,092 12.4% 14.6% 5.1% 5.9% +33% 160 120 +31% 50 65 Q2FY25 Q2FY26 Q2FY25 Q2FY26 Q2FY25 Q2FY2
14.6%
Revenue EBITDA & EBITDA Margin PAT & PAT Margin +13% 2,144 2,412 +14% 961 1,092 12.4% 14.6% 5.1% 5.9% +33% 160 120 +31% 50 65 Q2FY25 Q2FY26 Q2FY25 Q2FY26 Q2FY25 Q2FY26 Q2FY
5.1%
EBITDA & EBITDA Margin PAT & PAT Margin +13% 2,144 2,412 +14% 961 1,092 12.4% 14.6% 5.1% 5.9% +33% 160 120 +31% 50 65 Q2FY25 Q2FY26 Q2FY25 Q2FY26 Q2FY25 Q2FY26 Q2FY25 Q2
5.9%
DA & EBITDA Margin PAT & PAT Margin +13% 2,144 2,412 +14% 961 1,092 12.4% 14.6% 5.1% 5.9% +33% 160 120 +31% 50 65 Q2FY25 Q2FY26 Q2FY25 Q2FY26 Q2FY25 Q2FY26 Q2FY25 Q2FY26
33%
ITDA Margin PAT & PAT Margin +13% 2,144 2,412 +14% 961 1,092 12.4% 14.6% 5.1% 5.9% +33% 160 120 +31% 50 65 Q2FY25 Q2FY26 Q2FY25 Q2FY26 Q2FY25 Q2FY26 Q2FY25 Q2FY26 ⦁ Over
31%
PAT Margin +13% 2,144 2,412 +14% 961 1,092 12.4% 14.6% 5.1% 5.9% +33% 160 120 +31% 50 65 Q2FY25 Q2FY26 Q2FY25 Q2FY26 Q2FY25 Q2FY26 Q2FY25 Q2FY26 ⦁ Overall, the company h
216 bps
as reported a strong Gross and Net Revenue growth ⦁ EBITDA Margin has reported a healthy upside of 216 bps, with absolute EBITDA grew by 33% YoY Consolidated Financials 55 H1FY26 Performance Overview F
11%
Overview Figures in ₹ Cr. Gross Revenue Net Revenue EBITDA & EBITDA Margin PAT & PAT Margin +11% 4,426 4,916 +11% 1,930 2,133 12.8% 14.6% 5.7% 6.5% +25% 311 248 +26% 110 138
12.8%
Net Revenue EBITDA & EBITDA Margin PAT & PAT Margin +11% 4,426 4,916 +11% 1,930 2,133 12.8% 14.6% 5.7% 6.5% +25% 311 248 +26% 110 138 H1FY25 H2FY26 H1FY25 H1FY26 H1FY25 H1F
Guidance — 3 items
New range of products in pipeline
opening
FY23 FY24 FY25 FY23 FY24 FY25 EBITDA & EBITDA Margin (%) Adj.
New range of products in pipeline
opening
PAT Margin (%) 11.9% 319 12.9% 428 13.9% 525 5.3% 141 5.2% 173 6.1% 231 FY23 FY24 FY25 FY23 FY24 FY25 * PAT adjusted for Exceptional Income of ₹ 28.13 Cr.
New range of products in pipeline
opening
FY23-25 CAGR 16.7% 19.2% 18.9% 28.3% 34.9% 33.1% 28.0% 28.0% FY25 9,039 3,768 15 3,783 525 13.9% 115 410 164 - 46 292 61 231 - 231 6.1% 231 6.1% 74.6 * PAT adjusted for Exceptional Income of ₹ 28.13 Cr.
Risks & concerns — 2 flagged
 Reduction in volatile organic chemicals from the MEG plant.
New range of products in pipeline
 Effective risk management framework implementation.
New range of products in pipeline
Speaking time
Customised product design
1
Environment and eco-friendly
1
New range of products in pipeline
1
CIN
1
Opening remarks
Environment and eco-friendly
Biodegradable Technical collaborations & Tie-ups US-based Scientific Design Inc. to produce high-quality bio-glycols Global tech partnership with Wittemann, Hitachi, Air Liquide and Praxair Tie-up with Bacardi for bottling of their products at the Kashipur bottling unit LanzaTech for manufacturing of specialty chemicals based on C-smart alcohol Using world-renowned ‘Sulzer Chemtech’ technology for Glycol ethers and acetates - Only manufacturer in India JV with Clariant, leader in bio-based ethoxylates and derivatives
New range of products in pipeline
i) Products derived from C-smart or Purple alcohol ii) Bio Based specialties iii) iGreen solvents including a range of bio-esters, Specialty Bio-amines etc. iv) Specialty derivatives of Poly- galactomannans v) APIs and Nutraceuticals Focusing on following major industry sectors: i) Oil & Gas Industry including refineries, ii) Automobiles iii) Metal working Industry iv) Industrial and institutional cleaning v) Rheology modifiers for Petroleum Industry vi) Food Industry vii) Health care 34 Growth Drivers High prospects of growth of industry sectors being serviced by IGL – Personal Care, Automotive, Packaging, Beverages, Oil & Gas, Home Care, Pharma, Nutraceuticals etc, Textiles – most expected to grow at near double digit or more Increasing consumer awareness and demand for sustainable products Companies taking steps to significantly decrease carbon footprint in line with USDG targets Growing demand for natural and safer products in pharma, nutraceuticals, cosmeceuticals, food ingredient
CIN
L24111UR1983PLC009097 Head office 2B, Sector-126, Noida Gautam Budh Nagar Uttar Pradesh 201304 Ankur Jain Company Secretary & Compliance Office Tel: +91-120-6860000, 3090100, 3090200 Fax: +91-120-3090111 Email: investor.relations@indiaglycols.com Ernst & Young LLP Rohit Anand rohit.anand4@in.ey.com Riddhant Kapur Riddhant.kapur@in.ey.com
← All transcriptsINDIAGLYCO stock page →